News
ASH: Regeneron makes frontline case for Lynozyfic in myeloma
Regeneron's BCMAxCD3 bispecific Lynozyfic is the first drug in the class to show efficacy as a monotherapy in first-line multiple myeloma.
Monday 12 January 2026
